United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - chenopodium album pollen (unii: 098lkx5ncn) (chenopodium album pollen - unii:098lkx5ncn) - chenopodium album pollen 0.1 g in 1 ml - allergenic extracts are indicated for use in diagnosis and immunotherapy of patients presenting symptoms of allergy (hay fever, rhinitis, etc.) to specific environmental allergens. the selection of allergenic extracts to be used should be based on a thorough and carefully taken history of hypersensitivity, and confirmed by skin testing. the use of mixed or unrelated antigens for skin testing is not recommended since, in the case of a positive reaction, it does not indicate which component of the mix is responsible for the reaction, while, in the case of a negative reaction, it fails to indicate whether the individual antigens at full concentration would give a positive reaction. utilization of such mixes for compounding a treatment may result, in the former case, in administering unnecessary antigens and, in the latter case, in the omission of a needed antigen. avoidance of allergens is to be advocated if possible, but cannot always be attained, e.g., allergy to dog dander in kennel owners and employees,

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 10 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (chicken (33%), duck (33%), goose (33%) feathers extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

New Zealand - English - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 10 ic/ml (equine epithelium extract) - solution for injection - 10 ic/ml - active: allergen extracts 10 ic/ml (equine epithelium extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

allergy therapeutics (uk) ltd - fat hen (chenopodium species) pollen allergen extract; nettle (urtica dioica) pollen allergen extract; plantain (plantago lanceolata) pollen allergen extract; atriplex species pollen allergen extract; mugwort (artemisia vulgaris) pollen allergen extract - solution for skin-prick test

United States - English - NLM (National Library of Medicine)

allermed laboratories, inc. - cotton seed (unii: di0zrj0mxn) (cotton seed - unii:di0zrj0mxn) - alnus rhombifolia pollen 0.05 g in 1 ml - allergenic extract may be used as a diagnostic skin test reagent in persons suspected of being sensitive to the allergenic source material from which the extract is made. skin tests should be used in conjunction with a thorough allergic history to establish the relevance of a given allergen in the etiology of allergic disease. 4,5,6 immunotherapy with allergenic extract is indicated in persons suffering from allergic rhinitis, bronchitis, conjunctivitis, urticaria and asthma. the therapeutic efficacy of allergenic extract has been proven in ragweed, grass, and mountain cedar pollinosis, cat-induced asthma and hypersensitivity to hymenoptera venoms. 7-12 immunotherapy may be used along with or exclusive of antihistamines and other medications used to control allergic symptoms. allergenic extract should not be administered to a non-allergic person. however, there are no absolute contraindications to the use of allergenic extract for treatment in appropriate individuals. relativ

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - quercus rubra pollen (unii: svw19et93c) (quercus rubra pollen - unii:svw19et93c), quercus alba pollen (unii: z4y9zsv4kk) (quercus alba pollen - unii:z4y9zsv4kk), quercus virginiana pollen (unii: 8kdg09a4go) (quercus virginiana pollen - unii:8kdg09a4go) - crab leg, unspecified 0.1 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

United States - English - NLM (National Library of Medicine)

alk-abello, inc. - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), aspergillus repens (unii: sq89e6lome) (aspergillus repens - unii:sq89e6lome), aspergillus flavus var. oryzae (unii: q6z8uk5r3g) (aspergillus flavus var. oryzae - unii:q6z8uk5r3g), aspergillus terreus (unii: qbn8k7055x) (aspergillus terreus - unii:qbn8k7055x) - fraxinus americana pollen 0.05 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - salix nigra pollen (unii: 6m2jih93zn) (salix nigra pollen - unii:6m2jih93zn) - salix nigra pollen 0.05 g in 1 ml - certain diagnostics carry labeling which states allergenic extract for diagnostic use only . data to support the therapeutic use of products labeled with this statement have not been established. 14 in addition to a carefully taken history, the use of glycerin-containing extracts in scratch, prick or puncture testing is an accepted method in the diagnosis of allergic conditions. 1, 2, 3 extracts of all allergens do not produce equivalent results in scratch, prick or puncture tests. the intensity of the skin reactions produced will be determined by two factors: the degree of sensitivity of the patient, and the nature of the allergenic extract applied. scratch, prick or puncture tests are not as sensitive as the intradermal test, but are safer and cause less discomfort. they may, therefore, be the method of choice when a large number of tests are needed, or when testing the pediatric patient. in some cases, where the relatively insensitive scratch, prick or puncture tests are negative or do not confirm the

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - olea europaea, quantity: 10 ir/ml - injection, suspension - excipient ingredients: sodium chloride; phenol; mannitol; aluminium hydroxide hydrate; water for injections - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - olea europaea, quantity: 10 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; mannitol; phenol; water for injections - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.